AZN Jan 2025 42.500 put
| Previous Close | 0.0800 |
| Open | 0.0600 |
| Bid | 0.0300 |
| Ask | 0.1300 |
| Strike | 42.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.0600 - 0.0600 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 153 |
ZacksAstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
Business WireCALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
WILMINGTON, Del., October 03, 2024--AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
Simply Wall St.3 UK Stocks Estimated To Be Trading Below Their Intrinsic Value
The UK stock market has recently faced challenges, with the FTSE 100 index experiencing declines due to weak trade data from China and broader global economic concerns. As investors navigate these uncertain conditions, identifying stocks that are trading below their intrinsic value can present potential opportunities for those seeking to capitalize on mispriced assets.
